Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:ageRange |
18 years and older
|
| gptkbp:allocates |
Randomized
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:conditionStudied |
Obesity
Heart Failure With Preserved Ejection Fraction |
| gptkbp:enrollment |
~1000 participants
|
| gptkbp:gender |
All
|
| https://www.w3.org/2000/01/rdf-schema#label |
NCT04072952
|
| gptkbp:intervention |
gptkb:Placebo
Tirzepatide |
| gptkbp:location |
gptkb:Canada
gptkb:Europe gptkb:United_States |
| gptkbp:mask |
Double-blind
|
| gptkbp:officialName |
A Study to Evaluate the Efficacy and Safety of Tirzepatide in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) With Obesity (SURMOUNT-HF)
|
| gptkbp:recognizedBy |
gptkb:NCT04072952
|
| gptkbp:result |
Change from baseline in body weight at 52 weeks
Change from baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score at 52 weeks |
| gptkbp:sponsor |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:startDate |
2020-01-13
|
| gptkbp:status |
Recruiting
|
| gptkbp:studyID |
I8F-MC-GPHD
|
| gptkbp:studyType |
Interventional
|
| gptkbp:title |
A Study to Evaluate the Efficacy and Safety of Tirzepatide in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) With Obesity (SURMOUNT-HF)
|
| gptkbp:bfsParent |
gptkb:Targeted_Protein_Degradation
gptkb:ARV-471 |
| gptkbp:bfsLayer |
8
|